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est hazard ratio associated with models that were not 
fully adjusted in this study was 4.65, it seems unlikely 
that thigh circumference will be clinically useful.
If a risk prediction model that incorporates thigh cir‑
cumference in addition to other known risk factors is to 
be incorporated into usual practice, we need to ensure 
several things—firstly, that the new model discriminates 
better (has a higher c‑statistic) than existing models; 
secondly, that it is well calibrated—that the predicted 
and observed risk estimates for each stratum of risk 
are similar; and thirdly, that using the new model will 
lead to an appropriate change in intended management 
in more patients now correctly reclassified as having 
higher or lower risk than would be the case using exist‑
ing risk prediction models.
More research is needed to see whether measuring 
the thigh circumference with a tape measure adds any‑
thing more to our clinical management than eliciting 
risk factors from the history, examining the cardiovas‑
cular system, and measuring serum lipids. Randomised 
trials are needed to test whether interventions that 
increase thigh muscle mass through increased physi‑
cal activity—in addition to or separate from current 
primary prevention strategies—decrease cardiovascu‑
lar risk more than current practice. If this approach is 
shown to be effective, the public health implications 
would be intriguing. 
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can financial incentives improve health equity?
evidence shows that they might, if targeted appropriately
Recently, much interest has been shown in how 
financial incentives can increase health enhancing 
behaviours.1‑3 Two centres are studying the subject—
the Centre for the Study of Incentives in Health (a 
joint initiative between King’s College, Queen Mary, 
and the London School of Economics; www.kcl.ac.uk/
schools/biohealth/research/csincentiveshealth/) and 
the Center for Health Incentives at the University 
of Pennsylvania (www.med.upenn.edu/ldichi/). By 
encouraging healthier behaviours, it is hoped that 
incentives will help to contain healthcare costs and 
improve health. If the incentives motivate people in 
higher socioeconomic groups more than those in lower 
socioeconomic groups, however, they could exacer‑
bate health inequalities. In the linked analysis article, 
Schmidt and colleagues highlight this as a potential 
problem in Germany, where a sickness fund rewards 
people for engaging in preventive activities and for 
minimising use of health care, which might encourage 
the less well off to forgo needed health care.1
These are legitimate concerns, but we should not 
conclude that all incentives harm health equity. Stud‑
ies across a range of interventions have shown that 
people within lower socioeconomic groups do some‑
times respond significantly to incentives. Most of these 
studies were conducted in the United States, but their 
findings should be applicable to other countries.
For example, vouchers redeemable for fruit juice 
significantly increased concentrations of β carotene in 
pregnant women on low incomes.4 This finding con‑
curs with the Organisation for Economic Co‑operation 
and Development’s recent recommendation that cash 
payments or food vouchers should be offered to mate‑
rially deprived pregnant women to boost the take‑up of 
antenatal services.5 Early visits to childhood health cen‑
tres and uptake of vaccinations have been increased by 
financial incentives in Mexico, Nicaragua, Colombia, 
and Jamaica.2 A $10 (£6; €6.8) incentive significantly 
increased the uptake of mammograms in women on 
low incomes aged 40‑64 years.6 Financial incentives 
have also improved participation of intravenous drug 
users in a hepatitis B vaccination programme and a 
tuberculosis treatment programme.7 8 Several other 
examples of the positive effects of financial incentives 
have been published.9 10
These studies show that in some areas of health care 
modest financial incentives can substantially affect the 
behaviours of the relatively poor. Healthcare incentives 
do not always have a positive effect, however, and evi‑
dence of a positive sustained effect on more complex 
lifestyle behaviours, such as smoking or weight loss, is 
lacking.3
Some of the studies may have volunteer bias— 
volunteers may be particularly motivated to change their 
behaviour—and few studies provide adequate information 
on costs, let alone value for money. Moreover, the stud‑
ies do not test the differential effect of incentives on the 
relatively poor versus the better off. Because less wealthy 
people do respond to incentives, health inequalities could 
be reduced if incentives were targeted at them.
Targeting certain groups is controversial because it 
can breed resentment in the untargeted population. This 
can undermine solidarity, a key feature of European 
healthcare systems. Also, should the target be set at 
the family level (for example, families whose income 
is below a certain amount) or the geographical level 
(poor communities)? Because pockets of wealth often 
exist in poor communities, targeting at the family level 
seems the most sensible choice. Targeted interventions 
may be the best option in the current global financial 
climate because they are less expensive than those 
aimed at the population.
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Evidence indicates that appropriately targeted 
incentives could reduce inequalities in health out‑
comes. Ongoing assessment of their affordability, 
effectiveness, cost effectiveness, and unintended con‑
sequences is needed. Irrespective of the effectiveness 
of incentives, some people will argue that they do 
not tackle the root cause of poverty, and that money 
and health behaviours are incommensurate goods.11 
Like all tools, financial incentives may have unfortu‑
nate consequences unless handled with care, but it 
seems premature and irresponsible to exclude them 
c ompletely from the policymaking kitbag.
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Screening for intracranial aneurysms in aDPKD
A more accurate risk assignment model is needed
Autosomal dominant polycystic kidney disease 
(ADPKD) is one of the most common monogenic 
human diseases, with an incidence of 1 in 1000. 
Asymptomatic aneurysms can be detected in 6% of 
patients with ADPKD without a family history, but 
in up to 16% of patients with a family history.1 This 
compares with an estimated prevalence of 1‑2% in the 
general population. Intracranial aneurysm rupture is 
a rare but devastating complication of AKPKD that 
occurs on average 10 years younger than sporadic 
intracranial aneurysms. The youngest reported case 
was a 13 week old infant, and in one study 10% of 
patients were younger than 21 years.2 Intracranial 
aneurysm rupture is associated with a death rate of 
up to 65%. Treatment of a ruptured intracranial aneu‑
rysm by either neurosurgical clipping or endovas‑
cular treatment also carries an unacceptably high 
mortality rate of 8‑10% and morbidity (disability or 
dependency) rate of 16‑21%.3 
The risk of rupture of asymptomatic intracranial 
aneurysms occurring in the general population is 
primarily determined by size, location, and a his‑
tory of rupture.4 For instance, the rate of rupture for 
intracranial aneurysms less than 10 mm in diameter 
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